These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. Ginsberg HN; Le NA; Goldberg IJ; Gibson JC; Rubinstein A; Wang-Iverson P; Norum R; Brown WV J Clin Invest; 1986 Nov; 78(5):1287-95. PubMed ID: 3095375 [TBL] [Abstract][Full Text] [Related]
5. Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-alpha-triglyceridemia. Carlson LA; Holmquist L; Nilsson-Ehle P Acta Med Scand; 1986; 219(5):435-47. PubMed ID: 3739751 [TBL] [Abstract][Full Text] [Related]
6. Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a). Sandholzer C; Feussner G; Brunzell J; Utermann G J Clin Invest; 1992 Nov; 90(5):1958-65. PubMed ID: 1430218 [TBL] [Abstract][Full Text] [Related]
7. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia. Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797 [TBL] [Abstract][Full Text] [Related]
8. Severe hypertriglyceridaemia associated with altered apolipoprotein C and E composition of the triglyceride-rich lipoproteins. Stalenhoef AF; Demacker PN; Lutterman JA; Van't Laar A Neth J Med; 1981; 24(4):145-51. PubMed ID: 7279085 [No Abstract] [Full Text] [Related]
9. Adipose tissue lipoprotein lipase activity in type III hyperlipoproteinemia. Goldberg AP; Applebaum-Bowden DM; Hazzard WR Metabolism; 1979 Nov; 28(11):1122-6. PubMed ID: 226832 [TBL] [Abstract][Full Text] [Related]
10. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia. Saku K; Sasaki J; Arakawa K Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372 [TBL] [Abstract][Full Text] [Related]
11. Is decreased activity of C-II activated lipoprotein lipase in type III hyperlipoproteinemia (broad-beta-disease) a cause or an effect of increased apolipoprotein E levels? Ganesan D; Bass HB; McConathy WJ; Alaupovic P Metabolism; 1976 Nov; 25(11):1189-95. PubMed ID: 185483 [TBL] [Abstract][Full Text] [Related]
12. Recent progress in the development of radioimmunoassays for human serum lipoproteins. Karlin JB; Juhn DJ; Goldberg R; Rubenstein AH Ann Clin Lab Sci; 1978; 8(2):142-54. PubMed ID: 205163 [TBL] [Abstract][Full Text] [Related]
13. The role of high density lipoprotein apolipoprotein CII in triglyceride metabolism. Kashyap ML; Srivastava LS; Hynd BA; Perisutti G; Brady DW; Gartside P; Glueck CJ Lipids; 1978 Dec; 13(12):933-42. PubMed ID: 220489 [No Abstract] [Full Text] [Related]
14. Gemfibrozil: effect on serum lipids, lipoproteins, postheparin plasma lipase activities and glucose tolerance in primary hypertriglyceridaemia. Nikkilä EA; Ylikahri R; Huttunen JK Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):58-63. PubMed ID: 190608 [TBL] [Abstract][Full Text] [Related]
15. Effect of heparin-induced lipolysis on the distribution of apolipoprotein e among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase. Rubinstein A; Gibson JC; Paterniti JR; Kakis G; Little A; Ginsberg HN; Brown WV J Clin Invest; 1985 Feb; 75(2):710-21. PubMed ID: 3973025 [TBL] [Abstract][Full Text] [Related]
16. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, k1 values and apolipoprotein composition of the major lipoprotein density classes. Wang CS; Alaupovic P; Gregg RE; Brewer HB Biochim Biophys Acta; 1987 Jul; 920(1):9-19. PubMed ID: 3109493 [TBL] [Abstract][Full Text] [Related]
18. Studies of a variant very-low-density lipoprotein with an acquired deficiency of apolipoprotein C-II. Reckless JP; Stocks J; Holdsworth G; Galton DJ; Suggett AJ; Walton KW Clin Sci (Lond); 1982 Jan; 62(1):93-100. PubMed ID: 7056035 [TBL] [Abstract][Full Text] [Related]
19. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins. Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484 [TBL] [Abstract][Full Text] [Related]
20. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]